A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,674 shares of NTLA stock, worth $61,466. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,674
Previous 2,880 27.57%
Holding current value
$61,466
Previous $64,000 17.19%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$19.72 - $27.36 $15,657 - $21,723
794 Added 27.57%
3,674 $75,000
Q2 2024

Jul 30, 2024

SELL
$20.02 - $27.22 $4.29 Million - $5.84 Million
-214,514 Reduced 98.68%
2,880 $64,000
Q1 2024

May 01, 2024

BUY
$23.82 - $32.8 $751,187 - $1.03 Million
31,536 Added 16.97%
217,394 $5.98 Million
Q4 2023

Jan 24, 2024

SELL
$23.16 - $32.34 $2.34 Million - $3.26 Million
-100,885 Reduced 35.18%
185,858 $5.67 Million
Q3 2023

Oct 26, 2023

BUY
$31.62 - $45.78 $715,655 - $1.04 Million
22,633 Added 8.57%
286,743 $9.07 Million
Q2 2023

Aug 10, 2023

BUY
$34.58 - $46.03 $1.6 Million - $2.13 Million
46,381 Added 21.3%
264,110 $10.8 Million
Q1 2023

May 04, 2023

BUY
$33.3 - $44.82 $314,951 - $423,907
9,458 Added 4.54%
217,729 $8.11 Million
Q4 2022

Feb 09, 2023

SELL
$33.21 - $62.69 $104,677 - $197,598
-3,152 Reduced 1.49%
208,271 $7.27 Million
Q3 2022

Nov 10, 2022

BUY
$53.92 - $71.7 $1.72 Million - $2.29 Million
31,898 Added 17.77%
211,423 $11.8 Million
Q2 2022

Jul 26, 2022

BUY
$38.49 - $76.21 $3.99 Million - $7.9 Million
103,651 Added 136.61%
179,525 $9.29 Million
Q1 2022

May 10, 2022

SELL
$58.27 - $118.99 $798,706 - $1.63 Million
-13,707 Reduced 15.3%
75,874 $5.51 Million
Q4 2021

Feb 08, 2022

SELL
$100.76 - $138.36 $4.98 Million - $6.84 Million
-49,434 Reduced 35.56%
89,581 $10.6 Million
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $3.46 Million - $4.62 Million
26,113 Added 23.13%
139,015 $18.6 Million
Q2 2021

Aug 11, 2021

BUY
$60.88 - $161.91 $97,651 - $259,703
1,604 Added 1.44%
112,902 $18.3 Million
Q1 2021

May 13, 2021

BUY
$46.59 - $83.68 $2.35 Million - $4.23 Million
50,496 Added 83.05%
111,298 $8.93 Million
Q4 2020

Feb 10, 2021

BUY
$18.83 - $63.53 $446,270 - $1.51 Million
23,700 Added 63.88%
60,802 $3.31 Million
Q3 2020

Nov 12, 2020

BUY
$17.47 - $24.93 $206,058 - $294,049
11,795 Added 46.61%
37,102 $738,000
Q2 2020

Aug 11, 2020

BUY
$11.14 - $22.87 $107,512 - $220,718
9,651 Added 61.64%
25,307 $532,000
Q1 2020

May 12, 2020

BUY
$9.44 - $15.58 $16,066 - $26,517
1,702 Added 12.2%
15,656 $191,000
Q4 2019

Feb 12, 2020

BUY
$10.43 - $17.67 $35,535 - $60,201
3,407 Added 32.3%
13,954 $205,000
Q3 2019

Nov 12, 2019

BUY
$13.07 - $18.51 $137,849 - $195,224
10,547 New
10,547 $141,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.27B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.